UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy

Mediators of inflammation, 2017-01, Vol.2017, p.5620314-13

2017

Volltextzugriff (PDF)

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition

BioFactors (Oxford), 2020-05, Vol.46 (3), p.367-380

2020

Volltextzugriff (PDF)

Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies

Journal of cardiovascular medicine (Hagerstown, Md.), 2021-03, Vol.22 (3), p.151

2021

Volltextzugriff (PDF)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects

Pharmacological research, 2023-03, Vol.189, p.106664-106664, Article 106664

2023

Volltextzugriff (PDF)

Cardiac involvement in systemic sclerosis: ‘early diagnosis–early management’ approach

European journal of preventive cardiology, 2020-11, Vol.27 (17), p.1873-1875

2020

Volltextzugriff (PDF)

Letter by Calabrò et al Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)”

Circulation (New York, N.Y.), 2018-07, Vol.138 (2), p.218-219

2018

Volltextzugriff (PDF)

Coronary stent thickness: thinner is (always) better for all lesions?

Journal of cardiovascular medicine (Hagerstown, Md.), 2021-01, Vol.22 (1), p.26

2021

Volltextzugriff (PDF)

Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

Pharmacological research, 2023-01, Vol.187, p.106597-106597, Article 106597

2023

Volltextzugriff (PDF)

Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study

Journal of cardiovascular pharmacology, 2020-08, Vol.76 (2), p.173

2020

Volltextzugriff (PDF)

Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?

European heart journal supplements, 2022-11, Vol.24 (Supplement_I), p.I34-I37

2022

Volltextzugriff (PDF)

Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk

European journal of preventive cardiology, 2020-03, Vol.27 (5), p.556-558

2020

Volltextzugriff (PDF)

Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease

Circulation (New York, N.Y.), 2021-10, Vol.144 (16), p.1323-1343

2021

Volltextzugriff (PDF)

How has COVID-19 impacted the care of patients with acute coronary syndromes?

Expert review of cardiovascular therapy, 2023-01, Vol.21 (1), p.1-4

2023

Volltextzugriff (PDF)

Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go

Angiology, 2023-09, p.33197231201929-33197231201929

2023

Volltextzugriff (PDF)

Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

European journal of preventive cardiology, 2022-05, Vol.29 (5), p.832

2022

Volltextzugriff (PDF)

341 Observational multicentre study on effectiveness and tolerability of Alirocumab in real world, the OMERO study: interim data from the first 699 patients

European heart journal supplements, 2021-12, Vol.23 (Supplement_G)

2021

Volltextzugriff (PDF)

Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry)

The American journal of cardiology, 2019-12, Vol.124 (11), p.1662-1668

2019

Volltextzugriff (PDF)

Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease

Heart failure reviews, 2023-11, Vol.28 (6), p.1325-1334

2023

Volltextzugriff (PDF)

Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem

Cardiovascular drugs and therapy, 2024-01

2024

Volltextzugriff (PDF)

Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience

Journal of cardiovascular medicine (Hagerstown, Md.), 2018-02, Vol.19 (2), p.75

2018

Volltextzugriff (PDF)

1075 USE OF LIPID-LOWERING COMBINATION THERAPIES IN SANTORINI STUDY: EVIDENCE FROM ITALIAN COHORT

European heart journal supplements, 2022-12, Vol.24 (Supplement_K)

2022

Volltextzugriff (PDF)

Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?

Expert review of cardiovascular therapy, 2018-12, Vol.16 (12), p.951-962

2018

Volltextzugriff (PDF)

Artificial intelligence in cardiovascular prevention: new ways will open new doors

Journal of cardiovascular medicine (Hagerstown, Md.), 2023-05, Vol.24 (Suppl 2), p.e106

2023

Volltextzugriff (PDF)

Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation

Journal of cardiovascular medicine (Hagerstown, Md.), 2023-05, Vol.24 (Suppl 2), p.e156

2023

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Cardiovascular System & Cardiology
(28)
Cardiac & Cardiovascular Systems
(25)
Humans
(24)
Male
(7)
Treatment Outcome
(7)
Female
(6)
Middle Aged
(6)
Risk Factors
(6)
Atherosclerosis
(5)
Cardiology
(5)
Medicine
(5)
Peripheral Vascular Disease
(5)
Pharmacology & Pharmacy
(5)
Aged
(4)
Cardiovascular Disease
(4)
Cardiovascular Diseases - Prevention & Control
(4)
Coronary Artery Disease
(4)
Heart Failure
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition

Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies

Reply to SGLT-2 inhibitors: Post-infarction interventional effects

Cardiac involvement in systemic sclerosis: ‘early diagnosis–early management’ approach

Letter by Calabrò et al Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)”

Coronary stent thickness: thinner is (always) better for all lesions?

Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study

Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?

Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk

Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease

How has COVID-19 impacted the care of patients with acute coronary syndromes?

Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia

Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

341 Observational multicentre study on effectiveness and tolerability of Alirocumab in real world, the OMERO study: interim data from the first 699 patients

Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry)

Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease

Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem

Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience

1075 USE OF LIPID-LOWERING COMBINATION THERAPIES IN SANTORINI STUDY: EVIDENCE FROM ITALIAN COHORT

Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?

Artificial intelligence in cardiovascular prevention: new ways will open new doors

Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation

Aktive Filter

Suchergebnisse filtern